Literature DB >> 10954198

Structural studies of matrix metalloproteinases.

N Borkakoti1.   

Abstract

The zinc- and calcium-dependent family of proteins called the matrix metalloproteinases are collectively responsible for the degradation of the extracellular matrix. Members of this family such as the collagenases, stromelysins and the gelatinases are involved in the routine tissue remodelling processes such as wound healing, embryonic growth and angiogenesis. Under normal circumstances the proteolytic activity of these proteins are precisely controlled at the transcriptional level, the production of the proteins in their inactive zymogen forms and also by the co-secretion of endogenous inhibitors. Imbalance between the active enzymes and their natural inhibitors leads to the accelerated destruction of connective tissue associated with the pathology of diseases such as rheumatoid and osteoarthritis. The potential for using specific enzyme inhibitors as therapeutic agents to redress this balance has led to intensive research focused on the design, syntheses and molecular structural analyses of low molecular weight inhibitors of this family of proteins. This review describes the essential structural principles and molecular interactions implicated in the innovation of matrix metalloproteinase inhibitors and discusses the features necessary for the specific inhibition of the collagenases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10954198     DOI: 10.1007/s001090000113

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  13 in total

1.  An extracellular matrix-associated zinc metalloprotease is required for dilauroyl phosphatidylethanolamine chemotactic excitation in Myxococcus xanthus.

Authors:  Daniel B Kearns; Pamela J Bonner; Daniel R Smith; Lawrence J Shimkets
Journal:  J Bacteriol       Date:  2002-03       Impact factor: 3.490

2.  Conformational variability of matrix metalloproteinases: beyond a single 3D structure.

Authors:  Ivano Bertini; Vito Calderone; Marta Cosenza; Marco Fragai; Yong-Min Lee; Claudio Luchinat; Stefano Mangani; Beatrice Terni; Paola Turano
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-04       Impact factor: 11.205

3.  Inhibition of matrix metalloproteinases enhances in vitro repair of the meniscus.

Authors:  Amy L McNulty; J Brice Weinberg; Farshid Guilak
Journal:  Clin Orthop Relat Res       Date:  2008-10-31       Impact factor: 4.176

4.  Matrix metalloproteinases and cardiovascular diseases.

Authors:  A Papazafiropoulou; N Tentolouris
Journal:  Hippokratia       Date:  2009-04       Impact factor: 0.471

Review 5.  Circulating glioma biomarkers.

Authors:  Johan M Kros; Dana M Mustafa; Lennard J M Dekker; Peter A E Sillevis Smitt; Theo M Luider; Ping-Pin Zheng
Journal:  Neuro Oncol       Date:  2014-09-24       Impact factor: 12.300

6.  Refined-mapping of the novel TSG within the 17q24.3 chromosomal region in non-small cell lung cancer samples.

Authors:  Wayren Huang; Yiching Wang; Woeichyn Chu; Ruochia Tseng
Journal:  Oncol Lett       Date:  2016-07-05       Impact factor: 2.967

Review 7.  Ovarian cancer: involvement of the matrix metalloproteinases.

Authors:  Linah Al-Alem; Thomas E Curry
Journal:  Reproduction       Date:  2015-04-27       Impact factor: 3.906

8.  Inflammageing assessed by MMP9 in normal Japanese individuals and the patients with Werner syndrome.

Authors:  Makoto Goto; Junji Chiba; Masaaki Matsuura; Sachiko Iwaki-Egawa; Yasuhiro Watanabe
Journal:  Intractable Rare Dis Res       Date:  2016-05

9.  Characteristics of aortic wall extracellular matrix in patients with acute myocardial infarction: tissue microarray detection of collagen I, collagen III and elastin levels.

Authors:  Chee Hoe Kong; Xiao Yun Lin; Chin Cheng Woo; Hung Chew Wong; Chuen Neng Lee; A Mark Richards; Vitaly A Sorokin
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-10-09

Review 10.  Structural aspects of the metzincin clan of metalloendopeptidases.

Authors:  F Xavier Gomis-Rüth
Journal:  Mol Biotechnol       Date:  2003-06       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.